Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissues.
An immunohistochemical assay was used to assess expression of ras p21 and myc p62 oncogene products in human hepatocellular carcinoma (HCC) and non-neoplastic liver tissues. The monoclonal antibodies Y13 259 and Myc1-9E10, specific for ras p21 and myc p62 oncoproteins, were employed on paraffin-embedded sections. Most HCCs showed enhanced ras p21 and myc p62 expression, as indicated by staining intensity. Cirrhotic livers revealed increased myc p62 and occasionally increased ras p21 expression. HBsAg+ hepatocytes showed intense immunostaining for ras p21. Fibrotic, cholestatic, fetal and normal adult liver did not present enhancement of oncoprotein production. We suggest that combined over-expression of ras and myc oncoproteins may be important for the malignant phenotypic alteration in human HCC.
Tiniakos
D
D
Department of Pathology, NIMTS Hospital, Athens, Greece.
Spandidos
D A
DA
Kakkanas
A
A
Pintzas
A
A
Pollice
L
L
Tiniakos
G
G
D006528:Carcinoma, Hepatocellular / Q000032:analysis* / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D008099:Liver / Q000032:analysis*; D008113:Liver Neoplasms / Q000032:analysis* / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D016271:Proto-Oncogene Proteins c-myc; D016283:Proto-Oncogene Proteins p21(ras)
D011518:Proto-Oncogene Proteins; D016271:Proto-Oncogene Proteins c-myc; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)